ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Gout Pipeline Landscape Report 2021 - ResearchAndMarkets.com

September 29, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Sep 29, 2021--

The “Gout - Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.

ADVERTISEMENT

Gout Emerging Drugs Chapters

This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gout Emerging Drugs

SEL 212: Selecta Biosciences

Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.

URC 102: JW Pharmaceuticals

JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition mechanism of action and promotes uric acid excretion.

Major Players in Gout

There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.

Gout: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.

Key Questions Answered

ADVERTISEMENT

  • How many companies are developing Gout drugs?
  • How many Gout drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gout and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Selecta Biosciences
  • JW Pharmaceuticals
  • Astrazeneca
  • Revive Therapeutics
  • Fuji Yakuhin Co., Ltd.
  • Arthrosi Therapeutics

Key Products

  • SEL 212
  • URC 102
  • Verinurad
  • AR882
  • FYU-981

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/nd2o6n

View source version on businesswire.com:https://www.businesswire.com/news/home/20210929005589/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 09/29/2021 09:28 AM/DISC: 09/29/2021 09:28 AM

http://www.businesswire.com/news/home/20210929005589/en